{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086271","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.952090+00:00","generated_at":"2026-05-31T12:05:38.614277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rigel Q2 revenue $36.8M, net loss narrows to $1.0M; GAVRETO launch adds $1.9M","bullets":["Total Q2 revenue $36.8M; TAVALISSE $26.4M (+24% YoY), REZLIDHIA $5.2M (+102% YoY), GAVRETO $1.9M (launched June 27).","Net loss narrowed to $1.0M ($0.06/share) from $6.6M loss in Q2 2023; approaching net income break-even.","Completed NDA transfer of GAVRETO; product commercially available from Rigel beginning June 27.","Phase 1b trial of R289 in LR-MDS enrolling fourth dose level; preliminary data expected by end of 2024.","Cash and investments $49.1M as of June 30, essentially flat from March 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086271","json":"https://secwatch.observer/filing/0001104659-24-086271.json","markdown":"https://secwatch.observer/filing/0001104659-24-086271.md","text":"https://secwatch.observer/filing/0001104659-24-086271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924086271/0001104659-24-086271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924086271/tm2420634d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:05:38.614277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}